Case Studies
01
Viral Clearance Programs
In April 2025, a certain Innovative Drug Research and Development Center Co., Ltd. received the "Drug Clinical Trial Approval Notice" for its self-developed injection for the treatment of advanced solid tumors, approved by the National Medical Products Administration (NMPA).
Read More
02
Cell & Gene Therapy Programs
On January 29, 2026, SYS6055 Injection, independently developed by CSPC Pharmaceutical Group, obtained the clinical trial implied approval from the National Medical Products Administration (NMPA)
Read More
03
Commercialization & BLA Support
On January 8, 2026, a leading innovative biopharmaceutical company announced the market approval of its self-developed recombinant human thyroid stimulating hormone (rhTSH) for injection.
Read More
